nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—ABCB1—Vismodegib—skin cancer	0.0851	0.557	CbGbCtD
Dabigatran etexilate—ABCB1—Dactinomycin—skin cancer	0.0447	0.292	CbGbCtD
Dabigatran etexilate—F2—leg—skin cancer	0.0304	0.106	CbGeAlD
Dabigatran etexilate—F2—forelimb—skin cancer	0.0302	0.105	CbGeAlD
Dabigatran etexilate—F2—hindlimb—skin cancer	0.0271	0.0943	CbGeAlD
Dabigatran etexilate—F2—appendage—skin cancer	0.0233	0.0809	CbGeAlD
Dabigatran etexilate—ABCB1—Docetaxel—skin cancer	0.0231	0.151	CbGbCtD
Dabigatran etexilate—F2—endothelium—skin cancer	0.0141	0.0488	CbGeAlD
Dabigatran etexilate—F2—blood vessel—skin cancer	0.013	0.045	CbGeAlD
Dabigatran etexilate—CES2—nipple—skin cancer	0.0104	0.0363	CbGeAlD
Dabigatran etexilate—NQO2—nipple—skin cancer	0.00933	0.0324	CbGeAlD
Dabigatran etexilate—F2—neck—skin cancer	0.00927	0.0322	CbGeAlD
Dabigatran etexilate—UGT2B15—female reproductive system—skin cancer	0.00855	0.0297	CbGeAlD
Dabigatran etexilate—CES1—neck—skin cancer	0.00851	0.0296	CbGeAlD
Dabigatran etexilate—CES2—skin of body—skin cancer	0.00669	0.0233	CbGeAlD
Dabigatran etexilate—F2—connective tissue—skin cancer	0.00664	0.0231	CbGeAlD
Dabigatran etexilate—F2—epithelium—skin cancer	0.00631	0.0219	CbGeAlD
Dabigatran etexilate—CES2—mammalian vulva—skin cancer	0.0061	0.0212	CbGeAlD
Dabigatran etexilate—CES1—connective tissue—skin cancer	0.0061	0.0212	CbGeAlD
Dabigatran etexilate—NQO2—mammalian vulva—skin cancer	0.00545	0.0189	CbGeAlD
Dabigatran etexilate—UGT2B7—female reproductive system—skin cancer	0.00522	0.0182	CbGeAlD
Dabigatran etexilate—CES2—female reproductive system—skin cancer	0.00522	0.0182	CbGeAlD
Dabigatran etexilate—F2—lymphoid tissue—skin cancer	0.00486	0.0169	CbGeAlD
Dabigatran etexilate—F2—female reproductive system—skin cancer	0.00469	0.0163	CbGeAlD
Dabigatran etexilate—NQO2—female reproductive system—skin cancer	0.00467	0.0162	CbGeAlD
Dabigatran etexilate—CES1—lymphoid tissue—skin cancer	0.00446	0.0155	CbGeAlD
Dabigatran etexilate—CES2—head—skin cancer	0.00436	0.0152	CbGeAlD
Dabigatran etexilate—CES1—female reproductive system—skin cancer	0.0043	0.015	CbGeAlD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00426	0.182	CbGpPWpGaD
Dabigatran etexilate—F2—head—skin cancer	0.00391	0.0136	CbGeAlD
Dabigatran etexilate—NQO2—head—skin cancer	0.0039	0.0136	CbGeAlD
Dabigatran etexilate—CES1—head—skin cancer	0.00359	0.0125	CbGeAlD
Dabigatran etexilate—CES2—lymph node—skin cancer	0.00306	0.0106	CbGeAlD
Dabigatran etexilate—ABCB1—blood vessel—skin cancer	0.00279	0.00969	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—skin cancer	0.00273	0.00949	CbGeAlD
Dabigatran etexilate—CES1—lymph node—skin cancer	0.00252	0.00875	CbGeAlD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00251	0.107	CbGpPWpGaD
Dabigatran etexilate—Dermatitis—Vismodegib—skin cancer	0.00199	0.00371	CcSEcCtD
Dabigatran etexilate—Back pain—Imiquimod—skin cancer	0.00197	0.00368	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Docetaxel—skin cancer	0.00196	0.00366	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Vemurafenib—skin cancer	0.00195	0.00364	CcSEcCtD
Dabigatran etexilate—Dysphagia—Dactinomycin—skin cancer	0.00194	0.00361	CcSEcCtD
Dabigatran etexilate—Infection—Vemurafenib—skin cancer	0.00194	0.00361	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Fluorouracil—skin cancer	0.00191	0.00357	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Vemurafenib—skin cancer	0.00191	0.00357	CcSEcCtD
Dabigatran etexilate—Skin disorder—Vemurafenib—skin cancer	0.00189	0.00353	CcSEcCtD
Dabigatran etexilate—Nausea—Vismodegib—skin cancer	0.00187	0.0035	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Fluorouracil—skin cancer	0.00187	0.00348	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.00187	0.00348	CcSEcCtD
Dabigatran etexilate—Pneumonia—Bleomycin—skin cancer	0.00186	0.00348	CcSEcCtD
Dabigatran etexilate—Angioedema—Imiquimod—skin cancer	0.00186	0.00347	CcSEcCtD
Dabigatran etexilate—Syncope—Imiquimod—skin cancer	0.00183	0.00341	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Bleomycin—skin cancer	0.00183	0.00341	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.00183	0.00341	CcSEcCtD
Dabigatran etexilate—Hypotension—Vemurafenib—skin cancer	0.00182	0.0034	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Bleomycin—skin cancer	0.00182	0.00339	CcSEcCtD
Dabigatran etexilate—Palpitations—Imiquimod—skin cancer	0.0018	0.00336	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Imiquimod—skin cancer	0.00179	0.00334	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Temozolomide—skin cancer	0.00179	0.00334	CcSEcCtD
Dabigatran etexilate—Cough—Imiquimod—skin cancer	0.00178	0.00332	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00178	0.00331	CcSEcCtD
Dabigatran etexilate—Haematuria—Bleomycin—skin cancer	0.00177	0.00329	CcSEcCtD
Dabigatran etexilate—Hypertension—Imiquimod—skin cancer	0.00176	0.00328	CcSEcCtD
Dabigatran etexilate—Dysphagia—Temozolomide—skin cancer	0.00175	0.00327	CcSEcCtD
Dabigatran etexilate—Pneumonia—Dactinomycin—skin cancer	0.00174	0.00324	CcSEcCtD
Dabigatran etexilate—Chest pain—Imiquimod—skin cancer	0.00173	0.00324	CcSEcCtD
Dabigatran etexilate—Arthralgia—Imiquimod—skin cancer	0.00173	0.00324	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00172	0.00321	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Docetaxel—skin cancer	0.0017	0.00317	CcSEcCtD
Dabigatran etexilate—Bronchitis—Temozolomide—skin cancer	0.00169	0.00314	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00168	0.00314	CcSEcCtD
Dabigatran etexilate—Fatigue—Vemurafenib—skin cancer	0.00168	0.00314	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Bleomycin—skin cancer	0.00167	0.00312	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Fluorouracil—skin cancer	0.00167	0.00312	CcSEcCtD
Dabigatran etexilate—Constipation—Vemurafenib—skin cancer	0.00167	0.00311	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Bleomycin—skin cancer	0.00166	0.0031	CcSEcCtD
Dabigatran etexilate—Infection—Imiquimod—skin cancer	0.00165	0.00308	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—XRCC1—skin cancer	0.00164	0.0702	CbGpPWpGaD
Dabigatran etexilate—Shock—Imiquimod—skin cancer	0.00164	0.00305	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Imiquimod—skin cancer	0.00163	0.00304	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Temozolomide—skin cancer	0.00163	0.00304	CcSEcCtD
Dabigatran etexilate—Skin disorder—Imiquimod—skin cancer	0.00162	0.00301	CcSEcCtD
Dabigatran etexilate—Dysphagia—Fluorouracil—skin cancer	0.00161	0.00301	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Fluorouracil—skin cancer	0.00157	0.00293	CcSEcCtD
Dabigatran etexilate—Pneumonia—Temozolomide—skin cancer	0.00157	0.00293	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Temozolomide—skin cancer	0.00156	0.00291	CcSEcCtD
Dabigatran etexilate—Infestation—Temozolomide—skin cancer	0.00156	0.00291	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Temozolomide—skin cancer	0.00152	0.00283	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Imiquimod—skin cancer	0.00152	0.00283	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Fluorouracil—skin cancer	0.0015	0.0028	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.0015	0.0641	CbGpPWpGaD
Dabigatran etexilate—Cardiac failure congestive—Docetaxel—skin cancer	0.00149	0.00277	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Imiquimod—skin cancer	0.00148	0.00277	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Temozolomide—skin cancer	0.00148	0.00276	CcSEcCtD
Dabigatran etexilate—Sinusitis—Temozolomide—skin cancer	0.00147	0.00273	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Imiquimod—skin cancer	0.00146	0.00273	CcSEcCtD
Dabigatran etexilate—Pneumonia—Fluorouracil—skin cancer	0.00145	0.0027	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Fluorouracil—skin cancer	0.00144	0.00269	CcSEcCtD
Dabigatran etexilate—Infestation—Fluorouracil—skin cancer	0.00144	0.00269	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vemurafenib—skin cancer	0.00144	0.00268	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Imiquimod—skin cancer	0.00144	0.00268	CcSEcCtD
Dabigatran etexilate—Fatigue—Imiquimod—skin cancer	0.00143	0.00267	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Fluorouracil—skin cancer	0.00142	0.00265	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Fluorouracil—skin cancer	0.00141	0.00263	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Temozolomide—skin cancer	0.00141	0.00263	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Temozolomide—skin cancer	0.0014	0.00262	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Fluorouracil—skin cancer	0.0014	0.00261	CcSEcCtD
Dabigatran etexilate—Asthenia—Vemurafenib—skin cancer	0.0014	0.00261	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Temozolomide—skin cancer	0.00139	0.00258	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Temozolomide—skin cancer	0.00138	0.00258	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Docetaxel—skin cancer	0.00138	0.00258	CcSEcCtD
Dabigatran etexilate—Pruritus—Vemurafenib—skin cancer	0.00138	0.00257	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Temozolomide—skin cancer	0.00138	0.00257	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Temozolomide—skin cancer	0.00138	0.00256	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Imiquimod—skin cancer	0.00136	0.00254	CcSEcCtD
Dabigatran etexilate—Epistaxis—Fluorouracil—skin cancer	0.00136	0.00253	CcSEcCtD
Dabigatran etexilate—ABCB1—epithelium—skin cancer	0.00136	0.00472	CbGeAlD
Dabigatran etexilate—Sinusitis—Fluorouracil—skin cancer	0.00135	0.00252	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.00135	0.00252	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Docetaxel—skin cancer	0.00135	0.00252	CcSEcCtD
Dabigatran etexilate—Anaemia—Bleomycin—skin cancer	0.00134	0.0025	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vemurafenib—skin cancer	0.00133	0.00249	CcSEcCtD
Dabigatran etexilate—Urticaria—Imiquimod—skin cancer	0.00132	0.00246	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Imiquimod—skin cancer	0.00131	0.00245	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Temozolomide—skin cancer	0.0013	0.00243	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Fluorouracil—skin cancer	0.0013	0.00242	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Fluorouracil—skin cancer	0.00129	0.00241	CcSEcCtD
Dabigatran etexilate—Dizziness—Vemurafenib—skin cancer	0.00129	0.00241	CcSEcCtD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.00129	0.0551	CbGpPWpGaD
Dabigatran etexilate—Angiopathy—Temozolomide—skin cancer	0.00127	0.00237	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Temozolomide—skin cancer	0.00127	0.00236	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Temozolomide—skin cancer	0.00126	0.00236	CcSEcCtD
Dabigatran etexilate—Cough—Bleomycin—skin cancer	0.00126	0.00236	CcSEcCtD
Dabigatran etexilate—Anaemia—Dactinomycin—skin cancer	0.00125	0.00233	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Docetaxel—skin cancer	0.00124	0.00232	CcSEcCtD
Dabigatran etexilate—Vomiting—Vemurafenib—skin cancer	0.00124	0.00231	CcSEcCtD
Dabigatran etexilate—Chest pain—Bleomycin—skin cancer	0.00123	0.0023	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Docetaxel—skin cancer	0.00123	0.0023	CcSEcCtD
Dabigatran etexilate—Rash—Vemurafenib—skin cancer	0.00123	0.00229	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vemurafenib—skin cancer	0.00123	0.00229	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Imiquimod—skin cancer	0.00123	0.00229	CcSEcCtD
Dabigatran etexilate—Headache—Vemurafenib—skin cancer	0.00122	0.00228	CcSEcCtD
Dabigatran etexilate—Malnutrition—Temozolomide—skin cancer	0.00122	0.00228	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.00121	0.00226	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Docetaxel—skin cancer	0.00121	0.00225	CcSEcCtD
Dabigatran etexilate—Asthenia—Imiquimod—skin cancer	0.00119	0.00223	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Docetaxel—skin cancer	0.00119	0.00222	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Bleomycin—skin cancer	0.00118	0.0022	CcSEcCtD
Dabigatran etexilate—Back pain—Temozolomide—skin cancer	0.00118	0.0022	CcSEcCtD
Dabigatran etexilate—ABCB1—mammalian vulva—skin cancer	0.00118	0.00409	CbGeAlD
Dabigatran etexilate—Pruritus—Imiquimod—skin cancer	0.00118	0.00219	CcSEcCtD
Dabigatran etexilate—Infection—Bleomycin—skin cancer	0.00117	0.00219	CcSEcCtD
Dabigatran etexilate—Dysphagia—Docetaxel—skin cancer	0.00117	0.00217	CcSEcCtD
Dabigatran etexilate—Nausea—Vemurafenib—skin cancer	0.00116	0.00216	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Bleomycin—skin cancer	0.00116	0.00216	CcSEcCtD
Dabigatran etexilate—Bronchospasm—Docetaxel—skin cancer	0.00115	0.00214	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Imiquimod—skin cancer	0.00114	0.00212	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Docetaxel—skin cancer	0.00114	0.00212	CcSEcCtD
Dabigatran etexilate—Anaemia—Temozolomide—skin cancer	0.00113	0.00211	CcSEcCtD
Dabigatran etexilate—Angioedema—Temozolomide—skin cancer	0.00112	0.00208	CcSEcCtD
Dabigatran etexilate—Hypotension—Bleomycin—skin cancer	0.0011	0.00206	CcSEcCtD
Dabigatran etexilate—Dizziness—Imiquimod—skin cancer	0.0011	0.00205	CcSEcCtD
Dabigatran etexilate—Infection—Dactinomycin—skin cancer	0.00109	0.00204	CcSEcCtD
Dabigatran etexilate—Palpitations—Temozolomide—skin cancer	0.00108	0.00201	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Dactinomycin—skin cancer	0.00108	0.00201	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Bleomycin—skin cancer	0.00108	0.00201	CcSEcCtD
Dabigatran etexilate—Cough—Temozolomide—skin cancer	0.00107	0.00199	CcSEcCtD
Dabigatran etexilate—Vomiting—Imiquimod—skin cancer	0.00106	0.00197	CcSEcCtD
Dabigatran etexilate—Hypertension—Temozolomide—skin cancer	0.00105	0.00197	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Bleomycin—skin cancer	0.00105	0.00196	CcSEcCtD
Dabigatran etexilate—Rash—Imiquimod—skin cancer	0.00105	0.00196	CcSEcCtD
Dabigatran etexilate—Dermatitis—Imiquimod—skin cancer	0.00105	0.00195	CcSEcCtD
Dabigatran etexilate—Pneumonia—Docetaxel—skin cancer	0.00105	0.00195	CcSEcCtD
Dabigatran etexilate—ABCB1—lymphoid tissue—skin cancer	0.00104	0.00363	CbGeAlD
Dabigatran etexilate—Headache—Imiquimod—skin cancer	0.00104	0.00194	CcSEcCtD
Dabigatran etexilate—Anaemia—Fluorouracil—skin cancer	0.00104	0.00194	CcSEcCtD
Dabigatran etexilate—Arthralgia—Temozolomide—skin cancer	0.00104	0.00194	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Docetaxel—skin cancer	0.00104	0.00194	CcSEcCtD
Dabigatran etexilate—Infestation—Docetaxel—skin cancer	0.00104	0.00194	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00103	0.00193	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Docetaxel—skin cancer	0.00102	0.00191	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Docetaxel—skin cancer	0.00102	0.0019	CcSEcCtD
Dabigatran etexilate—ABCB1—female reproductive system—skin cancer	0.00101	0.0035	CbGeAlD
Dabigatran etexilate—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.001	0.00187	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Temozolomide—skin cancer	0.000997	0.00186	CcSEcCtD
Dabigatran etexilate—Infection—Temozolomide—skin cancer	0.00099	0.00185	CcSEcCtD
Dabigatran etexilate—Nausea—Imiquimod—skin cancer	0.000988	0.00184	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Docetaxel—skin cancer	0.000983	0.00183	CcSEcCtD
Dabigatran etexilate—Epistaxis—Docetaxel—skin cancer	0.00098	0.00183	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Temozolomide—skin cancer	0.000977	0.00182	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Temozolomide—skin cancer	0.000976	0.00182	CcSEcCtD
Dabigatran etexilate—Skin disorder—Temozolomide—skin cancer	0.000968	0.00181	CcSEcCtD
Dabigatran etexilate—CES1—E2F transcription factor network—XRCC1—skin cancer	0.000967	0.0414	CbGpPWpGaD
Dabigatran etexilate—Chest pain—Fluorouracil—skin cancer	0.000958	0.00179	CcSEcCtD
Dabigatran etexilate—Fatigue—Dactinomycin—skin cancer	0.00095	0.00177	CcSEcCtD
Dabigatran etexilate—Urticaria—Bleomycin—skin cancer	0.000939	0.00175	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Docetaxel—skin cancer	0.000938	0.00175	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Docetaxel—skin cancer	0.000933	0.00174	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Docetaxel—skin cancer	0.000921	0.00172	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Docetaxel—skin cancer	0.000919	0.00171	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Fluorouracil—skin cancer	0.000918	0.00171	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Docetaxel—skin cancer	0.000917	0.00171	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Docetaxel—skin cancer	0.000914	0.00171	CcSEcCtD
Dabigatran etexilate—Infection—Fluorouracil—skin cancer	0.000912	0.0017	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000908	0.00169	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000901	0.00168	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Fluorouracil—skin cancer	0.0009	0.00168	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Fluorouracil—skin cancer	0.000899	0.00168	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Temozolomide—skin cancer	0.000888	0.00166	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000884	0.0378	CbGpPWpGaD
Dabigatran etexilate—Dyspepsia—Temozolomide—skin cancer	0.000877	0.00164	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—skin cancer	0.000871	0.00162	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Bleomycin—skin cancer	0.00087	0.00162	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Docetaxel—skin cancer	0.000866	0.00161	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Temozolomide—skin cancer	0.00086	0.0016	CcSEcCtD
Dabigatran etexilate—Fatigue—Temozolomide—skin cancer	0.000859	0.0016	CcSEcCtD
Dabigatran etexilate—Hypotension—Fluorouracil—skin cancer	0.000858	0.0016	CcSEcCtD
Dabigatran etexilate—Constipation—Temozolomide—skin cancer	0.000852	0.00159	CcSEcCtD
Dabigatran etexilate—Asthenia—Bleomycin—skin cancer	0.000848	0.00158	CcSEcCtD
Dabigatran etexilate—Angiopathy—Docetaxel—skin cancer	0.000846	0.00158	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Docetaxel—skin cancer	0.000843	0.00157	CcSEcCtD
Dabigatran etexilate—ABCB1—head—skin cancer	0.000842	0.00293	CbGeAlD
Dabigatran etexilate—Mediastinal disorder—Docetaxel—skin cancer	0.000841	0.00157	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000837	0.00156	CcSEcCtD
Dabigatran etexilate—Pruritus—Bleomycin—skin cancer	0.000836	0.00156	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Fluorouracil—skin cancer	0.000819	0.00153	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Temozolomide—skin cancer	0.000815	0.00152	CcSEcCtD
Dabigatran etexilate—Malnutrition—Docetaxel—skin cancer	0.000812	0.00151	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—skin cancer	0.000812	0.00151	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Fluorouracil—skin cancer	0.000808	0.00151	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000793	0.00148	CcSEcCtD
Dabigatran etexilate—Urticaria—Temozolomide—skin cancer	0.000792	0.00148	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—skin cancer	0.000791	0.00147	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Temozolomide—skin cancer	0.000788	0.00147	CcSEcCtD
Dabigatran etexilate—Back pain—Docetaxel—skin cancer	0.000785	0.00147	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—skin cancer	0.000754	0.00141	CcSEcCtD
Dabigatran etexilate—Vomiting—Bleomycin—skin cancer	0.000751	0.0014	CcSEcCtD
Dabigatran etexilate—Anaemia—Docetaxel—skin cancer	0.000751	0.0014	CcSEcCtD
Dabigatran etexilate—Rash—Bleomycin—skin cancer	0.000745	0.00139	CcSEcCtD
Dabigatran etexilate—Dermatitis—Bleomycin—skin cancer	0.000744	0.00139	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Temozolomide—skin cancer	0.000734	0.00137	CcSEcCtD
Dabigatran etexilate—Urticaria—Fluorouracil—skin cancer	0.000729	0.00136	CcSEcCtD
Dabigatran etexilate—Syncope—Docetaxel—skin cancer	0.000728	0.00136	CcSEcCtD
Dabigatran etexilate—Palpitations—Docetaxel—skin cancer	0.000718	0.00134	CcSEcCtD
Dabigatran etexilate—Asthenia—Temozolomide—skin cancer	0.000715	0.00133	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Docetaxel—skin cancer	0.000714	0.00133	CcSEcCtD
Dabigatran etexilate—Cough—Docetaxel—skin cancer	0.000709	0.00132	CcSEcCtD
Dabigatran etexilate—Pruritus—Temozolomide—skin cancer	0.000705	0.00132	CcSEcCtD
Dabigatran etexilate—Nausea—Bleomycin—skin cancer	0.000702	0.00131	CcSEcCtD
Dabigatran etexilate—Hypertension—Docetaxel—skin cancer	0.000701	0.00131	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—skin cancer	0.000701	0.00131	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—skin cancer	0.000695	0.0013	CcSEcCtD
Dabigatran etexilate—Arthralgia—Docetaxel—skin cancer	0.000691	0.00129	CcSEcCtD
Dabigatran etexilate—Chest pain—Docetaxel—skin cancer	0.000691	0.00129	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000687	0.00128	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Temozolomide—skin cancer	0.000682	0.00127	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Fluorouracil—skin cancer	0.000677	0.00126	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—RASA1—skin cancer	0.000668	0.0286	CbGpPWpGaD
Dabigatran etexilate—Anaphylactic shock—Docetaxel—skin cancer	0.000663	0.00124	CcSEcCtD
Dabigatran etexilate—Dizziness—Temozolomide—skin cancer	0.000659	0.00123	CcSEcCtD
Dabigatran etexilate—Infection—Docetaxel—skin cancer	0.000658	0.00123	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—skin cancer	0.000654	0.00122	CcSEcCtD
Dabigatran etexilate—Shock—Docetaxel—skin cancer	0.000652	0.00122	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Docetaxel—skin cancer	0.00065	0.00121	CcSEcCtD
Dabigatran etexilate—Pruritus—Fluorouracil—skin cancer	0.00065	0.00121	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Docetaxel—skin cancer	0.000649	0.00121	CcSEcCtD
Dabigatran etexilate—Skin disorder—Docetaxel—skin cancer	0.000644	0.0012	CcSEcCtD
Dabigatran etexilate—Vomiting—Temozolomide—skin cancer	0.000634	0.00118	CcSEcCtD
Dabigatran etexilate—Rash—Temozolomide—skin cancer	0.000628	0.00117	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Fluorouracil—skin cancer	0.000628	0.00117	CcSEcCtD
Dabigatran etexilate—Dermatitis—Temozolomide—skin cancer	0.000628	0.00117	CcSEcCtD
Dabigatran etexilate—Headache—Temozolomide—skin cancer	0.000624	0.00116	CcSEcCtD
Dabigatran etexilate—Hypotension—Docetaxel—skin cancer	0.000619	0.00116	CcSEcCtD
Dabigatran etexilate—Dizziness—Fluorouracil—skin cancer	0.000607	0.00113	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000604	0.00113	CcSEcCtD
Dabigatran etexilate—Nausea—Temozolomide—skin cancer	0.000592	0.0011	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Docetaxel—skin cancer	0.000591	0.0011	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—skin cancer	0.00059	0.00205	CbGeAlD
Dabigatran etexilate—Vomiting—Fluorouracil—skin cancer	0.000584	0.00109	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Docetaxel—skin cancer	0.000583	0.00109	CcSEcCtD
Dabigatran etexilate—Rash—Fluorouracil—skin cancer	0.000579	0.00108	CcSEcCtD
Dabigatran etexilate—Dermatitis—Fluorouracil—skin cancer	0.000578	0.00108	CcSEcCtD
Dabigatran etexilate—Headache—Fluorouracil—skin cancer	0.000575	0.00107	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Docetaxel—skin cancer	0.000572	0.00107	CcSEcCtD
Dabigatran etexilate—Fatigue—Docetaxel—skin cancer	0.000571	0.00107	CcSEcCtD
Dabigatran etexilate—Constipation—Docetaxel—skin cancer	0.000567	0.00106	CcSEcCtD
Dabigatran etexilate—Nausea—Fluorouracil—skin cancer	0.000545	0.00102	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Docetaxel—skin cancer	0.000542	0.00101	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—skin cancer	0.000535	0.0229	CbGpPWpGaD
Dabigatran etexilate—Abdominal pain—Docetaxel—skin cancer	0.000524	0.000977	CcSEcCtD
Dabigatran etexilate—CES2—E2F transcription factor network—CDKN2A—skin cancer	0.00051	0.0218	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPARA activates gene expression—PLIN2—skin cancer	0.000495	0.0212	CbGpPWpGaD
Dabigatran etexilate—Hypersensitivity—Docetaxel—skin cancer	0.000488	0.000911	CcSEcCtD
Dabigatran etexilate—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PLIN2—skin cancer	0.000484	0.0207	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Docetaxel—skin cancer	0.000475	0.000887	CcSEcCtD
Dabigatran etexilate—Pruritus—Docetaxel—skin cancer	0.000469	0.000875	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Docetaxel—skin cancer	0.000453	0.000846	CcSEcCtD
Dabigatran etexilate—Dizziness—Docetaxel—skin cancer	0.000438	0.000817	CcSEcCtD
Dabigatran etexilate—Vomiting—Docetaxel—skin cancer	0.000421	0.000786	CcSEcCtD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CDK4—skin cancer	0.000419	0.0179	CbGpPWpGaD
Dabigatran etexilate—Rash—Docetaxel—skin cancer	0.000418	0.000779	CcSEcCtD
Dabigatran etexilate—Dermatitis—Docetaxel—skin cancer	0.000417	0.000779	CcSEcCtD
Dabigatran etexilate—Headache—Docetaxel—skin cancer	0.000415	0.000774	CcSEcCtD
Dabigatran etexilate—Nausea—Docetaxel—skin cancer	0.000394	0.000734	CcSEcCtD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000342	0.0146	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PLIN2—skin cancer	0.000334	0.0143	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—MC1R—skin cancer	0.000324	0.0139	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—skin cancer	0.000315	0.0135	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—CDKN2A—skin cancer	0.0003	0.0128	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTCH2—skin cancer	0.000229	0.0098	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000217	0.0093	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—EXOC2—skin cancer	0.00019	0.0081	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—MC1R—skin cancer	0.000166	0.00708	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PLIN2—skin cancer	0.00016	0.00684	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—PTGS2—skin cancer	0.000149	0.00637	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000143	0.00612	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RHOU—skin cancer	0.000142	0.00608	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000133	0.00568	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CSPG4—skin cancer	0.000129	0.00551	CbGpPWpGaD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—IL6—skin cancer	0.000126	0.00537	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—BRAF—skin cancer	0.000121	0.00517	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—SHH—skin cancer	0.000118	0.00505	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH2—skin cancer	0.000118	0.00503	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—SMO—skin cancer	0.000112	0.00478	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTCH1—skin cancer	0.000112	0.00478	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—skin cancer	0.000112	0.00477	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—PTGER4—skin cancer	0.000109	0.00466	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—skin cancer	0.000105	0.00451	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL6—skin cancer	0.000102	0.00437	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000102	0.00436	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—MC1R—skin cancer	9.36e-05	0.004	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—skin cancer	9.08e-05	0.00388	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO2—skin cancer	8.76e-05	0.00375	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MC1R—skin cancer	8.5e-05	0.00363	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—IL6—skin cancer	8.11e-05	0.00347	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	8e-05	0.00342	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—skin cancer	7.72e-05	0.0033	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—skin cancer	7.6e-05	0.00325	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	7.58e-05	0.00324	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLIN2—skin cancer	7.28e-05	0.00311	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH2—skin cancer	6.94e-05	0.00297	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—skin cancer	6.55e-05	0.0028	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PTGER4—skin cancer	6.15e-05	0.00263	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SHH—skin cancer	6.06e-05	0.00259	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLIN2—skin cancer	5.92e-05	0.00253	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CSPG4—skin cancer	5.87e-05	0.00251	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTCH1—skin cancer	5.74e-05	0.00246	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—SMO—skin cancer	5.74e-05	0.00246	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	5.67e-05	0.00243	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTGER4—skin cancer	5.59e-05	0.00239	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	5.49e-05	0.00235	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI2—skin cancer	5.26e-05	0.00225	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ERCC2—skin cancer	5.09e-05	0.00218	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MC1R—skin cancer	5.02e-05	0.00215	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GLI1—skin cancer	4.95e-05	0.00212	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	4.88e-05	0.00209	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CSPG4—skin cancer	4.77e-05	0.00204	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SUFU—skin cancer	4.69e-05	0.00201	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	4.15e-05	0.00177	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO2—skin cancer	3.99e-05	0.00171	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	3.97e-05	0.0017	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	3.9e-05	0.00167	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SHH—skin cancer	3.58e-05	0.00153	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RASA1—skin cancer	3.55e-05	0.00152	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SMO—skin cancer	3.39e-05	0.00145	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTCH1—skin cancer	3.39e-05	0.00145	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTGER4—skin cancer	3.3e-05	0.00141	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—skin cancer	3.24e-05	0.00139	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTGS2—skin cancer	3.05e-05	0.0013	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FOXO4—skin cancer	2.92e-05	0.00125	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—skin cancer	2.86e-05	0.00122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.79e-05	0.00119	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLIN2—skin cancer	2.71e-05	0.00116	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.54e-05	0.00108	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—skin cancer	2.46e-05	0.00105	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ERCC2—skin cancer	2.32e-05	0.000991	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CSPG4—skin cancer	2.19e-05	0.000936	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—skin cancer	2.19e-05	0.000935	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—skin cancer	2.09e-05	0.000895	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—skin cancer	1.95e-05	0.000833	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ERCC2—skin cancer	1.88e-05	0.000805	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.87e-05	0.000798	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.66e-05	0.000709	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—skin cancer	1.64e-05	0.000702	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—skin cancer	1.54e-05	0.00066	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—skin cancer	1.49e-05	0.000636	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—skin cancer	1.41e-05	0.000604	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTGS2—skin cancer	1.39e-05	0.000594	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—skin cancer	1.2e-05	0.000513	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—skin cancer	1.15e-05	0.000491	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTGS2—skin cancer	1.13e-05	0.000483	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—skin cancer	9.69e-06	0.000415	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ERCC2—skin cancer	8.64e-06	0.000369	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—skin cancer	8.34e-06	0.000357	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—skin cancer	7.42e-06	0.000317	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—skin cancer	7.09e-06	0.000303	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—skin cancer	6.79e-06	0.00029	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTGS2—skin cancer	5.18e-06	0.000222	CbGpPWpGaD
